-transparent.png){kind=logo}
Since October 1973, 185 patients 21 years of age or younger with primary osteogenic sarcoma of an extremity were treated with adjuvant chemotherapy. Twenty-five of the first fifty-two patients (48%) have remained free of disease for a median of 7 years. In the next chemotherapy protocol most patients had chemotherapy prior to amputation or resection, during which time the dose of high-dose methotrexate was escalated in many patients to that needed to shrink the primary tumor. For a median of 4 years 43 of 54 patients (80%) have remained free of disease. In the current protocol, the response of the primary tumor to chemotherapy with high-dose methotrexate was used to select postoperative adjuvant chemotherapy for the patient. With the latter approach 73 of 79 patients (92%) have remained continuously free of disease for a median of 2 years. This experience demonstrates the value of chemotherapy in increasing the cure rate in osteogenic sarcoma and that the response to preoperative chemotherapy can help select postoperative chemotherapy to produce an even higher potential cure rate for osteogenic sarcoma.
G Rosen, and
R C Marcove, and
A G Huvos, and
B I Caparros, and
J M Lane, and
A Nirenberg, and
A Cacavio, and
S Groshen
December 1981,
The Surgical clinics of North America,
G Rosen, and
R C Marcove, and
A G Huvos, and
B I Caparros, and
J M Lane, and
A Nirenberg, and
A Cacavio, and
S Groshen
October 1984,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
G Rosen, and
R C Marcove, and
A G Huvos, and
B I Caparros, and
J M Lane, and
A Nirenberg, and
A Cacavio, and
S Groshen
February 1978,
Cancer treatment reports,
G Rosen, and
R C Marcove, and
A G Huvos, and
B I Caparros, and
J M Lane, and
A Nirenberg, and
A Cacavio, and
S Groshen
February 1988,
European journal of cancer & clinical oncology,
G Rosen, and
R C Marcove, and
A G Huvos, and
B I Caparros, and
J M Lane, and
A Nirenberg, and
A Cacavio, and
S Groshen
May 1985,
Orthopedics,
G Rosen, and
R C Marcove, and
A G Huvos, and
B I Caparros, and
J M Lane, and
A Nirenberg, and
A Cacavio, and
S Groshen
July 1975,
Journal of clinical pharmacology,
G Rosen, and
R C Marcove, and
A G Huvos, and
B I Caparros, and
J M Lane, and
A Nirenberg, and
A Cacavio, and
S Groshen
January 1980,
Cancer clinical trials,
G Rosen, and
R C Marcove, and
A G Huvos, and
B I Caparros, and
J M Lane, and
A Nirenberg, and
A Cacavio, and
S Groshen
January 1978,
Journal of the National Cancer Institute,
G Rosen, and
R C Marcove, and
A G Huvos, and
B I Caparros, and
J M Lane, and
A Nirenberg, and
A Cacavio, and
S Groshen
July 2007,
Current opinion in oncology,
G Rosen, and
R C Marcove, and
A G Huvos, and
B I Caparros, and
J M Lane, and
A Nirenberg, and
A Cacavio, and
S Groshen
November 1975,
Cancer,
